Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Lenvatinib, sold under the brand name Lenvima among others, is an anti-cancer medication for the treatment of certain kinds of thyroid cancer and for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases.
Read the full article on WikipediaLocally advanced or metastatic differentiated thyroid cancer Clinical criteria: Treatment Phase: Initial treatment The condition must be refractory to radioactive iodine, AND The treatment must be the sole PBS-subsidised therapy for this condition, AND Patient must have symptomatic progressive disease prior to treatment; OR Patient must have progressive disease at critical sites with a high risk of morbidity or mortality where local control cannot be achieved by other measures, AND Patient must have thyroid stimulating hormone adequately suppressed, AND Patient must be one in whom surgery is inappropriate, AND Patient must not be a candidate for radiotherapy with curative intent, AND Patient must have a WHO performance status of 2 or less. Treatment criteria: Must be treated by a medical practitioner. Radioactive iodine refractory is defined as: (i) a lesion without iodine uptake on a radioactive iodine (RAI) scan; or (ii) having received a cumulative RAI dose of greater than or equal to 600 mCi; or (iii) progression within 12 months of a single RAI treatment; or (iv) progression after two RAI treatments administered within 12 months of each other.
Advanced (unresectable) Barcelona Clinic Liver Cancer Stage B or Stage C hepatocellular carcinoma Clinical criteria: Treatment Phase: Initial treatment The treatment must be the sole PBS-subsidised therapy for this condition, AND Patient must not be suitable for transarterial chemoembolisation, AND Patient must have a WHO performance status of 2 or less, AND Patient must have Child Pugh class A, AND The condition must be untreated with systemic therapy; OR Patient must have developed intolerance of a severity necessitating permanent treatment withdrawal, in the absence of disease progression, to any of the following: (i) a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI), (ii) atezolizumab/bevacizumab combination therapy, (iii) durvalumab/tremelimumab combination therapy. Treatment criteria: Must be treated by a medical practitioner.
Stage IV clear cell variant renal cell carcinoma (RCC) Clinical criteria: Treatment Phase: Initial treatment Patient must have a prognostic International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) survival risk classification score at treatment initiation with this drug and pembrolizumab of either: (i) 1 to 2 (intermediate risk), (ii) 3 to 6 (poor risk); document the IMDC risk classification score in the patient's medical records, AND The condition must be untreated, AND Patient must have a WHO performance status of 2 or less. Treatment criteria: Patient must be undergoing combination therapy consisting of: (i) pembrolizumab, (ii) lenvatinib; OR Patient must be undergoing monotherapy with this drug due to a contraindication/intolerance to the other drug in the combination mentioned above, requiring temporary/permanent discontinuation; document the details in the patient's medical records, AND Must be treated by a medical practitioner.
Advanced, metastatic or recurrent endometrial carcinoma Clinical criteria: Treatment Phase: Initial treatment Patient must have received prior treatment with platinum-based chemotherapy, AND The condition must be untreated with each of: (i) programmed cell death-1/ligand-1 (PD-1/PDL-1) inhibitor therapy, (ii) tyrosine kinase inhibitor therapy, AND Patient must have a World Health Organisation (WHO) Eastern Cooperative Oncology Group (ECOG) performance status score no higher than 1 prior to treatment initiation. Treatment criteria: Patient must be undergoing combination therapy consisting of: (i) pembrolizumab, (ii) lenvatinib; OR Patient must be undergoing monotherapy with this drug due to a contraindication/intolerance to the other drug in the combination mentioned above, requiring temporary/permanent discontinuation; document the details in the patient's medical records, AND Must be treated by a medical practitioner.
“Lenvatinib is a multi-targeted receptor tyrosine kinase inhibitor that blocks several key proteins involved in cancer-related signalling pathways. It inhibits the three main vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), as well as fibroblast growth factor receptors (FGFR1, FGFR2, FGFR3, and FGFR4), platelet-derived growth factor receptor (PDGFR) alpha, c-Kit, and the RET proto-oncogene. Inhibition of VEGFR2 is considered the primary cause of the most common side effect, hypertension. Lenvatinib exhibits strong inhibitory activity against VEGFR1, 2, and 3 RTKs, with Ki values of 1.3, 0.74, and 0.71 nM, respectively. It also inhibits FGFR1, 2, and 3 RTKs (Ki = 22, 8.2, and 15 nM, respectively), as well as RET and KIT (Ki = 1.5 and 11 nM, respectively).”
“28 hours”
Working under the parallel aged-care framework? Aged-care equivalent →